Why lupus trial monitoring is essential in 2026
Systemic lupus erythematosus (SLE) affects roughly 1.5 million Americans, with lupus nephritis developing in 40–60% of patients and representing the leading cause of lupus-related morbidity and mortality. After decades with only hydroxychloroquine and belimumab as approved therapies, the SLE pipeline is now among the most active in all of immunology.
The clinical trial landscape for lupus in 2026 is characterized by rapid evolution across multiple mechanisms:
- Type I interferon pathway blockade — anifrolumab (AstraZeneca) approved in 2021; multiple follow-on programs targeting IFNAR, TYK2, and upstream sensors entering trials
- B cell depletion and tolerance — obinutuzumab, ianalumab (BAFF/IL-21), and CD19 CAR-T programs (BMS-986325 from 2seventy bio) now in Phase 2/3
- CAR-T in autoimmune disease — the paradigm shift of 2024–2025; multiple groups now studying CD19-targeted CAR-T for refractory SLE with remarkable early results
- Plasma cell targeting — daratumumab (anti-CD38), BCMA-targeted approaches moving into SLE/LN
- Calcineurin inhibitors and JAK inhibitors — voclosporin approved for LN; multiple JAK inhibitor programs (upadacitinib, deucravacitinib) in SLE trials
- Complement system — C3, C5, and factor D inhibitors being studied in LN
Track every new SLE trial automatically
The lupus pipeline moves fast. Get a daily digest of new trials matching your therapeutic area and targets.
Get the Free DigestWhat we monitor for lupus
Our daily ClinicalTrials.gov pipeline can be configured for precise lupus trial tracking:
- Condition keywords: "systemic lupus erythematosus", "SLE", "lupus nephritis", "discoid lupus", "neuropsychiatric lupus", "NPSLE"
- Mechanism keywords: "IFNAR", "type I interferon", "CD19 CAR-T", "BAFF", "belimumab combination", "TYK2", "JAK inhibitor lupus"
- Organ manifestation: Filter to nephritis-specific trials vs. broader SLE trials
- Sponsor filter: Track industry programs (competitive landscape) or include academic investigator-initiated studies
- Phase filter: Phase 1 for early pipeline intelligence, Phase 2/3 for near-term competitive threats
The CAR-T revolution in autoimmune disease
Perhaps no development has reshaped the SLE trial landscape more than the application of CAR-T cell therapy to autoimmune disease. Early data from European academic centers (notably Erlangen) showed durable remission in refractory SLE after anti-CD19 CAR-T — a result that has triggered a wave of commercial and academic programs.
The competitive dynamics are moving extremely fast:
- Multiple biotech companies have launched SLE CAR-T programs following the academic proof-of-concept
- The target landscape is expanding: CD19, CD20, BCMA, and combinations being explored
- Manufacturing improvements (in vivo CAR-T, allogeneic approaches) are entering trials to address cost and access
- Regulatory agencies have signaled strong interest in accelerated pathways for truly refractory SLE
Missing a competitor's CAR-T program registration is not an option for any serious lupus BD or investment team.
Who uses lupus trial monitoring
- Immunology-focused biotech BD teams — tracking competitor programs in SLE, LN, and related autoimmune conditions
- Pharma pipeline analysts — monitoring approved drug combinator trials and label extension studies
- Rheumatology-focused CROs — identifying enrollment competition for active SLE/LN studies
- Lupus patient advocacy organizations — staying current on clinical trial options for patients
- Healthcare investors — tracking lupus pipeline milestones for portfolio companies
Track new lupus trials
Configure your SLE/LN profile in 2 minutes. Daily digest with new trials and status updates. Cancel anytime.
Start Free — No Credit Card538 active trials, 307 recruiting.
Industry sponsors run 217 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 115.
| Top industry sponsor | Active trials |
|---|---|
| AstraZeneca | 26 |
| Novartis Pharmaceuticals | 10 |
| Bristol-Myers Squibb | 8 |
| Biogen | 6 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 6 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| High Quality Evidence of Chinese Lupus Nephritis (HELP) NCT03001973 | Recruiting | Completion pushed: 2026-12 → 2029-12 | 2026-09-16 |
| Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus… NCT06475742 | Enrolling by Invitation | Completion pushed: 2028-05 → 2032-09 | 2026-09-12 |
| A Study to Continue the Administration of Deucravacitinib in Participants With… NCT06875960 | Recruiting | Completion pushed: 2026-12-01 → 2028-01-31 | 2026-09-10 |
| Predictors of ICU Admission and In-Hospital Mortality in Hospitalized Patients… NCT07783711 | Not Yet Recruiting | Primary endpoint(s) modified | 2026-08-27 |
| Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the… NCT06711146 | Recruiting | Primary endpoint(s) modified | 2026-08-25 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.